Suitability of Oral Rehydration Solution (ORS) for Use in the Cisplatin Short Hydration Method

Saito, Yoshitaka; Takekuma, Yoh; Kobayashi, Masaki; Shinagawa, Naofumi; Noguchi, Takuro; Takeuchi, Satoshi; Shimizu, Yasushi; Kinoshita, Ichiro; Dosaka‐Akita, Hirotoshi; Sugawara, Mitsuru

doi:10.21873/anticanres.15808

Cited by 4 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, they did not evaluate the aggravating action of DM alone, and an advanced CIN management strategy using magnesium supplementation was not conducted in the study. Our previous study suggested baseline DM complication as an independent risk factor for CIN development under CDDP short hydration although there was less power to evaluate the association 4 . This study aimed to evaluate whether CIN more frequently occurs in DM patients.…”

Section: Discussionmentioning

confidence: 97%

“…Oral hydration substitutes for intravenous hydration in the short hydration method 4 . Therefore, CINV control is important for sufficient oral hydration.…”

Section: Discussionmentioning

confidence: 99%

“…We hypothesized that the CIN incidence would be 10% in the control group and 30% in the DM group, with a patient ratio of 5:1, according to our previous research 4 . To achieve 80% power with an alpha error of 5%, the required sample size was 190 subjects in the control group and 38 subjects in the DM group.…”

Section: Methodsmentioning

confidence: 99%

“…All patients received the CDDP short hydration method, including 8 mEq of magnesium sulfate administration as described previously 4 . In addition, all regimens included the same antiemetic therapy according to the current guidelines 24 ; intravenous palonosetron 0.75 mg on day 1, oral aprepitant 125 mg on day 1 and 80 mg on days 2, 3, and dexamethasone 9.9 mg infusion on day 1 and 8 mg orally on days 2–4.…”

Section: Methodsmentioning

confidence: 99%

“…Many reports evaluate CIN risk factors, although most were conducted using old CDDP administration methods without sufficient CIN prophylaxis described above, suggesting some do not reflect real-world settings 12 – 22 . We have revealed that co-administration of non-steroid anti-inflammatory drugs (NSAIDs) and baseline comorbidity of diabetes mellitus (DM) are significantly associated with CIN incidence in the short hydration method, the most advanced CDDP administration method 4 . However, the results were obtained without sufficient power calculation.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Diabetes mellitus degenerates cisplatin-induced nephrotoxicity in short hydration method: a propensity score-matching analysis

Saito

Sakamoto²,

Takekuma³

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

Cisplatin (CDDP)-induced nephrotoxicity (CIN) is dose-limiting. We revealed that co-administration of non-steroid anti-inflammatory drugs and baseline comorbidity of diabetes mellitus (DM) are associated with CIN development in the short hydration method; however, the results were accessorily obtained without appropriate power calculation. This study aimed to demonstrate the influence of DM complications on CIN incidence in a real-world setting. Lung cancer patients receiving CDDP (≥ 75 mg/m2)-containing regimens with a short hydration method (n = 227) were retrospectively evaluated. The patients were divided into control and baseline DM complication groups. The primary endpoint was the evaluation of CIN incidence between the groups. Propensity score-matching was performed to confirm the robustness of the primary analysis results. CIN occurred in 6.8% of control and 27.0% of DM patients, respectively, with a significant difference in all-patient populations (P = 0.001). In addition, variation of serum creatinine and creatinine clearance significantly worsened in DM patients. Similar results were obtained in a propensity-matched population. Multivariate logistic regression analysis found that DM complication is a singular risk factor for CIN development (adjusted odds ratio; 4.31, 95% confidence interval; 1.62–11.50, P = 0.003). In conclusion, our study revealed that baseline DM complications significantly worsen CIN.

show abstract

Section: Discussionmentioning

confidence: 97%

“…Oral hydration substitutes for intravenous hydration in the short hydration method 4 . Therefore, CINV control is important for sufficient oral hydration.…”

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Diabetes mellitus degenerates cisplatin-induced nephrotoxicity in short hydration method: a propensity score-matching analysis

Saito

Sakamoto²,

Takekuma³

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients

Saito,

Kobayashi,

Tamaki

et al. 2023

Sci Rep

Self Cite

View full text Add to dashboard Cite

The occurrence of cisplatin (CDDP)-induced nephrotoxicity (CIN) has decreased with advancements in supportive care. In contrast, we reported that baseline diabetes mellitus (DM) complications significantly worsen CIN. This study aimed to determine further risk factors associated with CIN development in DM patients. Patients with thoracic cancer requiring DM pharmacotherapy, who received CDDP (≥ 60 mg/m2)-containing regimens using the short hydration method (n = 140), were enrolled in this retrospective multicenter observational study. The primary endpoint of the present study was the elucidation of risk factors (patient factors, DM medication influence, and treatment-related factors) associated with CIN development in patients with DM. Cisplatin-induced nephrotoxicity occurred in 22.1% of patients with DM. The median worst variation of serum creatinine levels and creatinine clearance (worst level − baseline level) was 0.16 mg/dL (range: − 0.12–1.41 mg/dL) and − 15.9 mL/min (− 85.5–24.3 mL/min), respectively. Multivariate logistic regression analyses identified female sex as the singular risk factor for CIN development in the DM population (adjusted odds ratio; 2.87, 95% confidence interval; 1.08–7.67, P = 0.04). Diabetes mellitus medication and treatment-related factors did not affect CIN development. In conclusion, our study revealed that female sex is significantly associated with CIN development in patients with DM and thoracic cancer.

show abstract

Evaluation of Prediabetes in Cisplatin-induced Nephrotoxicity in the Short Hydration Method: A Subgroup Analysis

SAITO,

SAKAMOTO,

KOBAYASHI

et al. 2024

In Vivo

View full text Add to dashboard Cite

Background/Aim: Cisplatin-induced nephrotoxicity (CIN) is one of the most attention-requiring adverse effects. We have reported that diabetes mellitus significantly increases the incidence of CIN in a short hydration method in real-world lung cancer treatment. However, the effect of prediabetes on CIN development remains unclear. This study investigated whether patients with prediabetes exhibit CIN at a greater rate during real-world cisplatin-including treatments as a subgroup analysis. Patients and Methods: This retrospective observational study enrolled patients with lung cancer receiving cisplatin treatment (≥75 mg/m 2 ) from May 2014 to January 2021 (n=169). Patients were divided into a prediabetes group (baseline HbA1c 5.7-6.4%) and a control group (baseline HbA1c <5.7%). The primary endpoint of this study was the incidence of CIN in all treatment cycles between the two groups. We also assessed variations in serum creatinine (SCr) levels and creatinine clearance (CCr). Results: CIN occurred in 4.7% of controls and 8.3% of patients with prediabetes in all cycles, with no significant difference (p=0.37). In contrast, variation of SCr levels and CCr was significantly worse in the prediabetes group [median variation level (range) 0.11 mg/dl (-0.11-0.46 mg/dl) and 0.12 mg/dl (-0.02-1.08 mg/d) in controls and prediabetes, p=0.04 for SCr; -12.9 ml/min (-54.1-4.9 ml/min) and -16.3 ml/min (-49.4-3.0 ml/min), p=0.02 for CCr, respectively]. These results were also confirmed during the first cycle of treatment. Conclusion: Patients with prediabetes did not develop problematic CIN, although they exhibited significant increases in SCr and decreases in CCr.Cisplatin is a cytotoxic chemotherapeutic agent used in treating lung, ovarian, head and neck, urological, and esophageal malignancies (1-3). However, it has potent adverse effects, including gastrointestinal symptoms, neurotoxicity, ototoxicity, and nephrotoxicity (3). Cisplatininduced nephrotoxicity (CIN) is one of the most important adverse effects of cisplatin treatment and affects ongoing and future treatment strategies. Because cisplatin is administered in a variety of treatment settings, including metastasis, perioperative treatment, and chemoradiotherapy, its management is important for effective and less onerous treatment. CIN is dose-dependent, cumulative, usually reversible (2, 3), and is the dose-limiting toxicity of cisplatin (3-5). CIN used to occur in 30-40% of patients (3). However, supportive care, including magnesium and appropriate diuretic administration with quality antiemetic treatment, has decreased its incidence to 0-10% (6).Many studies have evaluated the factors associated with CIN incidence, although cisplatin administration methods vary 800

show abstract

Suitability of Oral Rehydration Solution (ORS) for Use in the Cisplatin Short Hydration Method

Cited by 4 publications

References 0 publications

Diabetes mellitus degenerates cisplatin-induced nephrotoxicity in short hydration method: a propensity score-matching analysis

Diabetes mellitus degenerates cisplatin-induced nephrotoxicity in short hydration method: a propensity score-matching analysis

Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients

Evaluation of Prediabetes in Cisplatin-induced Nephrotoxicity in the Short Hydration Method: A Subgroup Analysis

Contact Info

Product

Resources

About